Two products now have updated
Australian Public Assessment
Report (AusPAR) guidance from the
Therapeutic Goods Administration.
Celgene’s Revlimid (lenalidomide),
indicated for treatment of patients
with newly diagnosed multiple
myeloma, has additional strength
capsules.
NOAC Pradaxa (dabigatran) from
Boehringer Ingelheim has extended
indications.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Feb 16
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.